MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis
Seminars in Liver Disease · 2026-06 · 46 (02) · 135-155
DOI: 10.1055/a-2908-1230 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 23.07.2026. Verfasst von Britton S Cartee und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Pittsburgh, Department of Pathology, United States. Hauptthemen laut MEDLINE: T-Lymphocytes, Lymphocyte Activation, Liver, Neuroinflammatory Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Health Sciences, Division of Microbiology and Infectious Diseases.
Abstract (Originalsprache)
“The liver is the origin of the veins and the source of the blood.”—De Usu Partium Galen. Galen's hepatocentric physiology foreshadowed the liver–brain axis, a network linking vagal signaling, cytokines, metabolites, and migratory immune cells. Central to the immune arm of this axis, the liver generates 25 to 50% of thoracic duct lymph, positioning hepatic lymphatic output as a significant, though not yet fully characterized, source of T cells and cytokines in systemic circulation, a contribution that increases with hepatic inflammation in chronic metabolic diseases. We propose that T lymphocytes are the key cellular effectors through which inflammation originating in the liver, propagating systemically, a process we term hepatosystemic inflammation, reaches the central nervous system (CNS). In metabolic dysfunction-associated steatotic liver disease, hepatosystemic inflammation generates peripheral “push signals” that may license T cells for CNS access, while neuroinflammatory “pull signals” at CNS barrier interfaces may establish permissive entry points. In conclusion, we propose that T cell licensing by hepatosystemic signals represents the immune arm of the liver–brain axis and a mechanistic bridge between metabolic liver disease and neuroimmune dysfunction and associated cognitive decline, and identifies candidate therapeutic targets along this cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Medicine, University of Pittsburgh, Department of Pathology, United States.
- School of Medicine, University of Pittsburgh, Department of Pharmacology and Chemical Biology, United States.
- Organ Pathobiology and Therapeutics Institute (OPTIn), School of Medicine, University of Pittsburgh, United States.
- Pittsburgh Liver Research Center (PLRC), School of Medicine, University of Pittsburgh, United States.
ORCID-Profile: Smita S Iyer
Förderung
- NIDDK NIH HHS
- National Institute of Health Sciences
- Division of Microbiology and Infectious Diseases
- NINDS NIH HHS
- NIAID NIH HHS
- NIA NIH HHS
Zitieren
APA
Cartee, B. S., Diniz, F., Rai, R. P., Pal, P. B., Srivastava, R., Rossmiller, D., Raeman, R., & Iyer, S. S. (2026). MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis. Seminars in Liver Disease, 46(02), 135-155. https://doi.org/10.1055/a-2908-1230
Vancouver
Cartee BS, Diniz F, Rai RP, Pal PB, Srivastava R, Rossmiller D, et al. MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis. Seminars in Liver Disease. 2026;46(02):135-155. doi:10.1055/a-2908-1230
BibTeX
@article{Cartee2026,
author = {Cartee, Britton S and Diniz, Fabiola and Rai, Ravi P and Pal, Pabitra B and Srivastava, Rahul and Rossmiller, Daniel and Raeman, Reben and Iyer, Smita S},
title = {MASH-Associated T Cell Activation and Neuroinflammation: Evidence for a Hepatosystemic Immune Axis},
journal = {Seminars in Liver Disease},
year = {2026},
volume = {46},
number = {02},
pages = {135--155},
doi = {10.1055/a-2908-1230}
}
EUVIMED